Cornerstone Pharmaceuticals Receives FDA Orphan Drug Designation - - BioPharm International

ADVERTISEMENT

Cornerstone Pharmaceuticals Receives FDA Orphan Drug Designation



Cornerstone Pharmaceuticals, a cancer metabolism-based therapeutics company, has been granted orphan-drug designation by FDA for CPI-613, the company's altered energy metabolism directed (AEMD) drug candidate for treating myelodysplastic syndrome (MDS).

Cornerstone Pharmaceuticals previously received orphan-drug designation for the use of CPI-613 in the treatment of acute myeloid leukemia and pancreatic carcinoma. CPI-613 induces cancer-specific inhibition of pyruvate dehydrogenase and alpha ketoglutarate dehydrogenase, key mitochondrial enzymes involved in cancer-cell metabolism. CPI-613 is currently being evaluated in Phase I, I/II, and Phase II trials in hematologic malignancies and solid tumors.

Source: Cornerstone Pharmaceuticals

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

AbbVie/Shire Deal Officially Off
October 20, 2014
Amgen Sues Sanofi and Regeneron over Patent for mAb Targeting PCSK9
October 20, 2014
EMA Works to Speed Up Ebola Treatment
October 20, 2014
Lilly to Close Manufacturing Facility in Puerto Rico
October 17, 2014
BioReliance Introduces New Predictive Assays
October 17, 2014
Author Guidelines

Click here